Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

• Main Authors: Irene Tang (Author), Lauren Schwimmer (Author), Shenda Gu (Author), Wei Wei Prior (Author), Hieu Van Tran (Author), Allan Chan (Author), Anna McClain (Author), Christopher C. Fraser (Author), Chunyan Sun (Author), Meimei Si (Author), Guijiang Wang (Author), Yunxia Zhao (Author), Ning Zhang (Author), Jiayu Fu (Author), Mengxin Liu (Author), Chuanzeng Cao (Author), Shihao Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cell surface molecules PD-L1 and CD47 are potent inhibitors of adaptive and innate anti-cancer immunity. We sought to generate a safe, therapeutic, bispecific antibody specifically targeting, and blocking both PD-L1 and CD47 inhibitory activity. Novel anti-PDL-1 and anti-CD47 antibodies with favorab...